SciSparc Ltd. has taken a strategic step to enhance its financial position by entering into an inducement agreement with L.I.A Pure Capital Ltd. This agreement allows for the conversion of a convertible promissory note worth over $2 million into ordinary shares of the company at a set price. This move is significant as it reflects the company's efforts to manage its financial obligations and potentially improve its liquidity.
On October 15, 2026, SciSparc Ltd. (ticker: SPRC) filed a report detailing this inducement offer, which involves the conversion of a convertible note issued earlier this year. The outstanding principal and accrued interest on the note total $2,023,039.21. The conversion price has been set at $1.50 per ordinary share, with no additional cash payment required from the holder.
Background
SciSparc Ltd. operates in the pharmaceutical preparations sector, specifically focusing on the development of innovative therapies. The company is listed on the Nasdaq and is categorized as a non-accelerated filer. Its filings indicate a commitment to transparency and regulatory compliance, with recent reports filed under the Securities Exchange Act of 1934.
What the Filing Says
The filing reveals that the company has offered L.I.A Pure Capital Ltd. the opportunity to convert its outstanding note into shares at the specified conversion price. The agreement states, "The Company offered the Holder the opportunity to convert the outstanding principal and accrued interest under the Note into ordinary shares of the Company, no par value (the 'Ordinary Shares'), at a conversion price of $1.50 per Ordinary Share." The transaction is expected to close around October 16, 2026.
Impact
This inducement offer may impact various stakeholders, including the company’s shareholders, potential investors, and the broader pharmaceutical industry. By converting debt into equity, SciSparc aims to reduce its liabilities and improve its capital structure, which could enhance investor confidence. The move may also set a precedent for other companies in the pharmaceutical preparations sector to consider similar strategies in managing their financial obligations.
What's Next
The filing indicates that the closing of the transaction is expected to occur shortly after the filing date, on or about October 16, 2026. However, no further details are provided regarding subsequent steps or additional filings following this transaction.